Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment
View/ Open
Impact
Scholar |
Other documents of the author: Morillas, Carlos; Feliciano, Rosa; Fernández Catalina, Pablo; Ponte, Carla; Botella, Marta; Rodrigues, João; Esmatjes Mompo, Enric; Lafita, Javier; Lizán, Luis; Llorente, Ignacio; Morales, Cristóbal; Navarro Pérez, Jorge; Orozco Beltrán, Domingo; Paz, Silvia; Ramírez de Arellano, Antonio; Cardoso, Cristina; Tribaldos Causadias de Suarez, Maribel
Metadata
Show full item recordcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadata
Title
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experimentAuthor (s)
Date
2015-10Publisher
Dove Medical PressISSN
1177-889XBibliographic citation
MORILLAS, Carlos, et al. Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient preference and adherence, 2015, vol. 9, p. 1443.Type
info:eu-repo/semantics/articlePublisher version
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612138/Version
info:eu-repo/semantics/publishedVersionSubject
Abstract
Objective
To assess Spanish and Portuguese patients’ and physicians’ preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effect ... [+]
Objective
To assess Spanish and Portuguese patients’ and physicians’ preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects.
Methods
An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the conditional logit model.
Results
Three-hundred and thirty (n=330) patients (49.7% female; mean age 62.4 [SD: 10.3] years, mean T2DM duration 13.9 [8.2] years, mean body mass index 32.5 [6.8] kg/m2, 41.8% received oral + injected medication, 40.3% received oral, and 17.6% injected treatments) and 221 physicians from Spain and Portugal (62% female; mean age 41.9 [SD: 10.5] years, 33.5% endocrinologists, 66.5% primary-care doctors) participated. Patients valued avoiding a gain in bodyweight of 3 kg/6 months (WTP: €68.14 [95% confidence interval: 54.55–85.08]) the most, followed by avoiding one hypoglycemic event/month (WTP: €54.80 [23.29–82.26]). Physicians valued avoiding one hypoglycemia/week (WTP: €287.18 [95% confidence interval: 160.31–1,387.21]) the most, followed by avoiding a 3 kg/6 months gain in bodyweight and decreasing cardiovascular risk (WTP: €166.87 [88.63–843.09] and €154.30 [98.13–434.19], respectively). Physicians and patients were willing to pay €125.92 (73.30–622.75) and €24.28 (18.41–30.31), respectively, to avoid a 1% increase in glycated hemoglobin, and €143.30 (73.39–543.62) and €42.74 (23.89–61.77) to avoid nausea.
Conclusion
Both patients and physicians in Spain and Portugal are willing to pay for the health benefits associated with improved diabetes treatment, the most important being to avoid hypoglycemia and gaining weight. Decreased cardiovascular risk and weight reduction became the third most valued attributes for physicians and patients, respectively. [-]
Rights
info:eu-repo/semantics/openAccess
This item appears in the folowing collection(s)
- MED_Articles [667]
The following license files are associated with this item: